Background
==========

Treatment of poorly controlled type 2 diabetes (T2DM) in patients with severe obesity is challenging. Not all affected individuals choose bariatric surgery or drug therapy ([@bib1]). Only a small proportion of patients with severe obesity achieve meaningful weight loss with conservative lifestyle interventions in primary care ([@bib2]). In general, health gains through lifestyle modification in patients who are overweight with T2DM require a weight reduction of 10% or more ([@bib3]). Commercial meal replacement programmes have recently shown promise in managing T2DM ([@bib4]), but side effects including constipation, dizziness, alopecia, nausea, headache, diarrhoea, abdominal pain and cholelithiasis are common ([@bib5]), and these interventions may not be cost effective ([@bib6]). The use of semi-skimmed milk (with micronutrient, salt and fibre supplementation) in a low-energy liquid diet (LELD) as an alternative to commercial meal replacement has not previously been described but may have therapeutic potential.

Case presentation
=================

A 45-year-old white male carpenter was referred by his GP to our bariatric clinic for assessment and management of severe obesity, complicated by poorly controlled T2DM of 10-year duration. He had well-controlled hypertension and dyslipidaemia and stable non-alcoholic steatohepatitis. He was taking a basal bolus insulin regime of insulin aspart 20, 18 and 22 units with meals and insulin glargine 40 units nocte, a total dose of 100 insulin units per day. He was also taking metformin 500 mg three times daily, ramipril 2.5 mg once daily, simvastatin 30 mg once daily and aspirin 75 mg once daily. He did not drink alcohol and had stopped smoking 6 months previously with a 26 pack year history. His mother and sister had T2DM. He was single and lived with two siblings. On systems review he had noted persistently elevated glucometer readings for several months, with thirst, polydipsia, polyuria and nocturia, consistent with poor glycaemic control. On examination, he weighed 113.8 kg, height 168.2 cm with a BMI of 40.2 kg/m^2^. His waist was 117 cm, hip 120 cm with a waist-to-hip ratio of 0.98. His BP was 105/62 mmHg. He had no evidence of retinopathy, neuropathy or cutaneous markers of insulin resistance.

Investigation
=============

At initial assessment his HbA1c was 72 mmol/mol (8.7%), confirming poor glycaemic control. His lipid profile was excellent with a total cholesterol of 3.3, LDL 0.8, HDL 1.0 and triglycerides of 1.9 mmol/L. Liver profile and iron studies, as well as renal and thyroid function tests were all normal. His ECG was normal except for right bundle branch block.

Treatment
=========

Various bariatric treatment options were discussed with the patient. He declined laparoscopic sleeve gastrectomy or GLP1 agonist therapy. There was no evidence of an underlying psychiatric or psychological disorder that required specialist input. He was assessed by the bariatric dietician and provided with advice on healthy eating. He was noted to have a large intake of sugary snacks as well as starchy carbohydrates (bread, potatoes) in his diet. Given his severe obesity and poor diabetes control despite insulin therapy and in the absence of other treatment options, the patient agreed to a trial of a milk-based 'LELD'. This consisted of three continuous 8-week phases, each with fortnightly clinical assessments. The patient's basal metabolic rate was estimated at 1983 kcal using the 'Mifflin St. Jeor' formula ([@bib7]). During the first (weight loss) phase lasting 8 weeks, he consumed an exclusively milk-based liquid diet, consisting of 2.2 L of semi-skimmed milk (equivalent to 1012 kcal, 75 g of protein, 36 g of fat and 113 g carbohydrate) divided in seven equal portions per day. The volume of milk prescribed was determined by the patient's protein requirements, in order to reduce muscle loss. To minimise the risk of micronutrient deficiencies, he took a combined multivitamin and mineral supplement as well as fibre (ispaghula husk 3.5 g twice daily) in order to mitigate the high risk of constipation and a stock cube for sodium replacement. He was seen by the consultant endocrinologist, bariatric nurse and dietitian and had bloods drawn every 2 weeks. During the second phase (weight stabilisation) from weeks 9 to 16 inclusive, there was a gradual reintroduction of low-calorie meals from a set menu, under the supervision of the bariatric dietitian with fortnightly visits continuing. During the third phase (weight maintenance) from weeks 17 to 24 inclusive, the milk-based component of the diet was stopped completely and a balanced diet was resumed, under dietetic supervision, with a similar calorific value to the exclusively milk-based liquid diet of approximately 1000 kcal daily.

Outcome and follow-up
=====================

Five months after his initial assessment, his diet and glycaemic control had improved, although he gained 1.6 kg (which we attributed to better endogenous insulinisation), as shown in [Fig. 1](#fig1){ref-type="fig"}. We started the LELD and he responded well, with his weight coming down from 115.2 kg (BMI: 40.7 kg/m^2^) to 101.2 kg (BMI: 35.8 kg/m^2^) after 8 weeks and 94.6 kg (BMI: 33.4 kg/m^2^) after 24 weeks, a reduction of 20.6 kg (7.3 kg/m^2^). His insulin was cautiously but rapidly titrated downwards from 100 units per day to zero within a week of commencing the LELD. Glucometer readings and HbA1c ([Fig. 1](#fig1){ref-type="fig"}) rapidly normalised. Fifteen months after commencing the LELD (21 months after initial assessment), he had regained 2.2 kg and had a normal HbA1c of 48 mmol/mol, off insulin therapy. However 6 months later, although his weight had come down further to 92.6 kg (BMI: 32.7 kg/m^2^), his glycaemic control had deteriorated markedly, with a HbA1c of 104 mmol/mol, without any apparent change in dietary behaviour ([Fig. 1](#fig1){ref-type="fig"}). While cognisant of the potential need to reintroduce insulin, we initially sought to intensify oral therapy and increased his metformin to 1 g twice daily, added linagliptin 5 mg once daily and canagliflozin 100 mg once daily, all of which were well tolerated. This led to a gradual and sustained improvement in HbA1c over the following months, such that 55 months after initial assessment, his HbA1c was 50 mmol/mol, his weight was 100.4 kg (BMI: 35.5 kg/m^2^) and he felt well.Figure 1Changes in HbA1c and BMI during and after milk-based meal replacement programme.

Discussion
==========

Although there is no evidence base for the use of a milk-based LELD in managing severe obesity and T2DM, we felt it was the best option for this patient because other treatments were declined and the patient expressed a preference for this approach. Clearly, this intervention would not be suitable for all similar patients but may be useful in a small subgroup. Attrition from such an intensive dietary regimen is likely to be high. Although milk may be less expensive than commercial dietary supplements, 14 visits over 6 months to the bariatric clinic, with physician, nurse and dietetic assessment and phlebotomy at each visit consume substantial resources and may offset any economic gains from reduced medication usage.

Of note, the patient's HbA1c had already improved substantially in the 5 months between initial assessment and starting the programme, which might indicate suboptimal adherence to insulin therapy at his initial presentation. As anticipated, the sustainability of the metabolic improvements seen during the intervention was an issue, with a requirement to 'rescue' the patient from poor glycaemic control with intensification of oral diabetes therapy 15 months after finishing the programme. While the accompanying weight loss at the time suggested the patient might need insulin reintroduced, with close monitoring, frequent clinic visits and the introduction of oral diabetes medications, we were able to avoid this. His poor glycaemic control along with weight loss suggested an 'absolute' insulin deficiency, and the reversibility of this without insulin treatment suggests the patient may have been prone to transient beta cell glucotoxicity which responded well to oral therapy. The fact that the patient gained weight at the same time that glycaemic control improved on oral agents that do not tend to cause weight gain suggests further that these drugs reversed relative beta cell dysfunction and enhanced endogenous insulinisation. Aside from reversal of glucotoxicity, these medications may have improved beta cell function through other mechanisms. For example, linagliptin, a dipeptidyl peptidase inhibitor, is known to increase beta cell mass and restore beta cell insulin secretion through alterations in levels of glucagon-like peptide-1. We did not measure insulin or islet cell auto-antibodies at any time, nor did we formally assess beta cell function as this was not felt to be necessary clinically, though had his clinical course proceeded less well, we would have, and future studies of the mechanistic basis for improvements in glycaemic control with this diet should consider this.

There has been much interest in the role of therapeutic ketosis in weight loss interventions ([@bib8]). Ketosis has been shown to attenuate increases in ghrelin and appetite that occur with dietary restriction ([@bib9]). However we did not measure ketones in this patient, so their contribution to our findings is uncertain. There may be unique characteristics of milk that account for some of the improvements we observed. Milk whey protein attenuates muscle loss in adults with obesity during very-low-calorie diets ([@bib10]). Milk enhances post-prandial glucose and lipid metabolism in men with obesity ([@bib11]). Mechanistic studies in cohorts of patients undergoing milk-based meal replacement would help to determine the programme's influence on energy intake and expenditure, food preference, ketones and other 'proximal' outcomes aside from weight and glycaemic control. Ideally prospective studies and randomised controlled trials could help to determine the efficacy, safety and cost effectiveness of milk-based meal replacement.
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